{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05989529",
            "orgStudyIdInfo": {
                "id": "80910613"
            },
            "organization": {
                "fullName": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Delving Into Borderline Personality Disorder Clinical Trial Experiences",
            "officialTitle": "Uncovering Clinical Trial Engagement Among Individuals With Borderline Personality Disorder",
            "therapeuticArea": [
                "Other"
            ],
            "study": "delving-into-borderline-personality-disorder-clinical-trial-experiences"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-08",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-08-04",
            "studyFirstSubmitQcDate": "2023-08-04",
            "studyFirstPostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-08-04",
            "lastUpdatePostDateStruct": {
                "date": "2023-08-14",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Power Life Sciences Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Taking part in medical study usually favors a particular demographic group. But there is limited research available to explain what trial attributes affect the completion of these specific demographic groups.\n\nThis study will admit a wide range of data on the clinical research experience of borderline personality disorder patients to determine which factors prevail in limiting a patient's ability to join or finish a trial.\n\nIt will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future borderline personality disorder patients."
        },
        "conditionsModule": {
            "conditions": [
                "Borderline Personality Disorder"
            ],
            "keywords": [
                "borderline personality disorder"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "CASE_CROSSOVER",
                "timePerspective": "PROSPECTIVE"
            },
            "enrollmentInfo": {
                "count": 500,
                "type": "ESTIMATED"
            }
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of patients who decide to enroll in a borderline personality disorder clinical research",
                    "timeFrame": "3 months"
                },
                {
                    "measure": "Rate of patients who remain in borderline personality disorder clinical research to trial completion",
                    "timeFrame": "12 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Aged \u2265 18 years old\n* Clinical diagnosis of Borderline Personality Disorder\n* Able to comprehend the investigational nature of the protocol and provide informed consent\n\nExclusion Criteria:\n\n* No diagnosis of Borderline Personality Disorder confirmed\n* Inability to perform regular electronic reporting\n* Patient does not understand, sign, and return consent form",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Patients with borderline personality disorder who are actively considering enrolling in an observational clinical trial but have not yet completed enrollment and randomization phases in said clinical trial.",
            "samplingMethod": "PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Michael B Gill",
                    "role": "CONTACT",
                    "phone": "415-900-4227",
                    "email": "bask@withpower.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael B Gill",
                    "affiliation": "Power Life Sciences Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Power Life Sciences",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael B Gill",
                            "role": "CONTACT",
                            "phone": "415-900-4227",
                            "email": "https://www.withpower.com/contact-us@withpower.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "33890928",
                    "type": "BACKGROUND",
                    "citation": "Garcia MC. [Treatment of borderline personality disorder with opioid antagonists: buprenorphine, nalmefene, naloxone and naltrexone in the treatment of dissociative symptoms, self-mutilation and suicidal behavior]. Vertex. 2020 Apr;XXX(148):1-10. doi: 10.53680/vertex.v30i148.122. Spanish."
                },
                {
                    "pmid": "37229394",
                    "type": "BACKGROUND",
                    "citation": "Kvarstein EH, Froyhaug M, Pettersen MS, Carlsen S, Ekberg A, Fjermestad-Noll J, Ulvestad DA, Gikling EL, Hjermann E, Lindberget K, Omvik S, Eikenaes IU, Hummelen B, Morken KTE, Wilberg T, Pedersen GAF. Improvement of personality functioning among people treated within personality disorder mental health services. A longitudinal, observational study. Front Psychiatry. 2023 May 9;14:1163347. doi: 10.3389/fpsyt.2023.1163347. eCollection 2023."
                },
                {
                    "pmid": "30559092",
                    "type": "BACKGROUND",
                    "citation": "Jacob GA, Hauer A, Kohne S, Assmann N, Schaich A, Schweiger U, Fassbinder E. A Schema Therapy-Based eHealth Program for Patients with Borderline Personality Disorder (priovi): Naturalistic Single-Arm Observational Study. JMIR Ment Health. 2018 Dec 17;5(4):e10983. doi: 10.2196/10983."
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "documentSection": {
        "largeDocumentModule": {
            "largeDocs": [
                {
                    "typeAbbrev": "ICF",
                    "hasProtocol": false,
                    "hasSap": false,
                    "hasIcf": true,
                    "label": "Informed Consent Form",
                    "date": "2023-08-04",
                    "uploadDate": "2023-08-04T09:03",
                    "filename": "ICF_000.pdf",
                    "size": 77049
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000010554",
                    "term": "Personality Disorders"
                },
                {
                    "id": "D000001883",
                    "term": "Borderline Personality Disorder"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001523",
                    "term": "Mental Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13462",
                    "name": "Personality Disorders",
                    "asFound": "Personality Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5161",
                    "name": "Borderline Personality Disorder",
                    "asFound": "Borderline Personality Disorder",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4815",
                    "name": "Mental Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M14473",
                    "name": "Psychotic Disorders",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}